Pineridge Advisors’s Myriad Genetics MYGN Stock Holding History

Pineridge Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-53	Closed	-$727	–	614
2024 Q4	$727	Hold	53	–	–	﹤0.01%	550
2024 Q3	$1.45K	Hold	53	–	–	﹤0.01%	480
2024 Q2	$1.3K	Hold	53	–	–	﹤0.01%	514
2024 Q1	$1.13K	Sell	53 -183	-78%	-$3.93K	﹤0.01%	509
2023 Q4	$4.52K	Buy	+236	New	+$4.08K	﹤0.01%	509

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Pineridge Advisors's MYGN Position: Q1 2025 in Review

Pineridge Advisors sold out of Myriad Genetics (MYGN) in Q1 2025, closing a stake of 53 shares — an estimated $727 sold.

Pineridge Advisors first reported a position in MYGN in Q4 2023 and held it in 5 quarters. The position peaked at $4.52K in Q4 2023. 228 funds tracked by Wall St. Rank hold MYGN as of Q1 2025.

Pineridge Advisors reported no remaining Myriad Genetics position as of Q1 2025 after selling out during the quarter.
Pineridge Advisors sold 53 Myriad Genetics shares in Q1 2025, an estimated $727.
Pineridge Advisors first reported a position in Myriad Genetics in Q4 2023 and held it in 5 quarters.
Pineridge Advisors's Myriad Genetics position peaked at $4.52K in Q4 2023.
228 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2025.

Based on Pineridge Advisors's 13F filing for Q1 2025, filed 30 Apr 2025.